Xilio Therapeutics Inc
XLO0.669USD
+0.019+2.92%
Close 12/19, 16:00（ET）Quotes delayed by 15 min
34.67MMarket Cap
LossP/E TTM
More Details of Xilio Therapeutics Inc Company
Xilio Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in discovering and developing tumor-activated immuno-oncology (I-O) therapies with the goal of significantly improving outcomes for people living with cancer without the systemic side effects of current I-O treatments. It is using its proprietary platform to build a pipeline of novel, tumor-activated I-O molecules that are designed to optimize the therapeutic index by localizing anti-tumor activity within the tumor microenvironment, including tumor-activated cytokines, antibodies, bispecific and immune cell engagers. Its pipeline products include Vilastobart (XTX101), XTX301, XTX501, and tumor-activated bispecific molecules and immune cell-engaging molecules. XTX101 is an investigational tumor-activated, Fc-enhanced, high-affinity binding anti-CTLA-4 monoclonal antibody. XTX301, a tumor-activated, engineered interleukin 12, or IL-12, therapy.
Xilio Therapeutics Inc Info
Ticker SymbolXLO
Company nameXilio Therapeutics Inc
IPO dateOct 22, 2021
CEORusso (Rene)
Number of employees64
Security typeOrdinary Share
Fiscal year-endOct 22
Address828 Winter Street
CityWALTHAM
Stock exchangeNASDAQ OMX - NASDAQ BASIC
CountryUnited States of America
Postal code02451
Phone16174304680
Websitehttps://xiliotx.com/
Ticker SymbolXLO
IPO dateOct 22, 2021
CEORusso (Rene)
Company Executives of Xilio Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Director
Independent Director
70.00K
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Christina Rossi
Ms. Christina Rossi
Independent Director
Independent Director
--
--
Dr. Aoife M. Brennan
Dr. Aoife M. Brennan
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Frankenfield
Mr. Christopher (Chris) Frankenfield
Chief Financial Officer and Operating Officer
Chief Financial Officer and Operating Officer
--
--
Dr. Robert W. (Rob) Ross, M.D.
Dr. Robert W. (Rob) Ross, M.D.
Independent Director
Independent Director
--
--
Dr. Akintunde (Tunde) Bello, Ph.D.
Dr. Akintunde (Tunde) Bello, Ph.D.
Director
Director
--
--
View more
Name
Name/Position
Position
Shareholding
Change
Dr. James Samuel Shannon, M.D.
Dr. James Samuel Shannon, M.D.
Independent Director
Independent Director
70.00K
--
Ms. Sara M. Bonstein
Ms. Sara M. Bonstein
Independent Director
Independent Director
--
--
Dr. Xu Yuan, Ph.D.
Dr. Xu Yuan, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel J. Curran, M.D.
Dr. Daniel J. Curran, M.D.
Independent Director
Independent Director
--
--
Mr. Paul J. Clancy
Mr. Paul J. Clancy
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Christina Rossi
Ms. Christina Rossi
Independent Director
Independent Director
--
--
Revenue Breakdown
FY2025Q2
FY2025Q1
FY2024
Relevant data have not been disclosed by the company yet.
By RegionUSD
Name
Revenue
Proportion
United States
8.08M
0.00%
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Dec 15
Updated: Mon, Dec 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
17.34%
GKCC, LLC
13.33%
Bain Capital Life Sciences Investors, LLC
8.70%
AbbVie, Inc.
8.28%
Coastlands Capital LP
8.25%
Other
44.09%
Shareholders
Shareholders
Proportion
Gilead Sciences Inc
17.34%
GKCC, LLC
13.33%
Bain Capital Life Sciences Investors, LLC
8.70%
AbbVie, Inc.
8.28%
Coastlands Capital LP
8.25%
Other
44.09%
Shareholder Types
Shareholders
Proportion
Corporation
44.59%
Investment Advisor
14.84%
Hedge Fund
9.31%
Venture Capital
4.16%
Investment Advisor/Hedge Fund
1.69%
Individual Investor
0.66%
Research Firm
0.02%
Other
24.72%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
65
13.13M
25.34%
-6.35M
2025Q2
74
35.70M
68.94%
+3.82M
2025Q1
76
35.65M
68.85%
+3.77M
2024Q4
70
35.35M
73.19%
+8.60M
2024Q3
67
30.96M
73.92%
+4.31M
2024Q2
73
31.95M
83.81%
+2.44M
2024Q1
95
22.55M
67.42%
+68.86K
2023Q4
95
18.91M
68.67%
-3.93M
2023Q3
95
21.43M
77.87%
-3.16M
2023Q2
97
21.93M
79.85%
-2.72M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Gilead Sciences Inc
9.11M
17.57%
--
--
Jun 30, 2025
GKCC, LLC
7.00M
13.51%
+7.00M
--
Jun 07, 2024
Bain Capital Life Sciences Investors, LLC
4.57M
8.81%
--
--
Jun 30, 2025
AbbVie, Inc.
4.35M
8.39%
+4.35M
--
Feb 11, 2025
Merck & Co Inc
1.48M
2.86%
--
--
Jun 30, 2025
Takeda Pharmaceutical Co Ltd
1.48M
2.85%
--
--
Jun 30, 2025
RiverVest Venture Partners, LLC
1.44M
2.78%
--
--
Sep 30, 2024
The Vanguard Group, Inc.
1.15M
2.22%
+15.31K
+1.35%
Jun 30, 2025
Morgan Stanley Smith Barney LLC
1.44M
2.79%
+307.19K
+27.01%
Jun 30, 2025
View more
Related ETFs
Updated: Sat, Dec 6
Updated: Sat, Dec 6
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Xilio Therapeutics Inc?
The top five shareholders of Xilio Therapeutics Inc are:
Gilead Sciences Inc holds 9.11M shares, accounting for 17.57% of the total shares.
GKCC, LLC holds 7.00M shares, accounting for 13.51% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 4.57M shares, accounting for 8.81% of the total shares.
AbbVie, Inc. holds 4.35M shares, accounting for 8.39% of the total shares.
Merck & Co Inc holds 1.48M shares, accounting for 2.86% of the total shares.
Gilead Sciences Inc holds 9.11M shares, accounting for 17.57% of the total shares.
GKCC, LLC holds 7.00M shares, accounting for 13.51% of the total shares.
Bain Capital Life Sciences Investors, LLC holds 4.57M shares, accounting for 8.81% of the total shares.
AbbVie, Inc. holds 4.35M shares, accounting for 8.39% of the total shares.
Merck & Co Inc holds 1.48M shares, accounting for 2.86% of the total shares.
What are the top three shareholder types of Xilio Therapeutics Inc?
The top three shareholder types of Xilio Therapeutics Inc are:
Gilead Sciences Inc
GKCC, LLC
Bain Capital Life Sciences Investors, LLC
Gilead Sciences Inc
GKCC, LLC
Bain Capital Life Sciences Investors, LLC
How many institutions hold shares of Xilio Therapeutics Inc (XLO)?
As of 2025Q3, 65 institutions hold shares of Xilio Therapeutics Inc, with a combined market value of approximately 13.13M, accounting for 25.34% of the total shares. Compared to 2025Q2, institutional shareholding has increased by -43.60%.
What is the biggest source of revenue for Xilio Therapeutics Inc?
In FY2025Q2, the -- business generated the highest revenue for Xilio Therapeutics Inc, amounting to -- and accounting for --% of total revenue.
